Exploring the level of agreement among different drug-drug interaction checkers: a comparative study on direct oral anticoagulants.

Direct-acting oral anticoagulants drug-drug interactions interaction checkers summary of product characteristics

Journal

Expert opinion on drug metabolism & toxicology
ISSN: 1744-7607
Titre abrégé: Expert Opin Drug Metab Toxicol
Pays: England
ID NLM: 101228422

Informations de publication

Date de publication:
22 Feb 2024
Historique:
medline: 22 2 2024
pubmed: 22 2 2024
entrez: 22 2 2024
Statut: aheadofprint

Résumé

Direct oral anticoagulants (DOACs) may be involved in drug-drug interactions (DDIs) potentially increasing the risk of adverse drug reactions. This study aimed to evaluate the level of agreement among interaction checkers (ICs) and DOACs' summary of product characteristics (SPCs), in listing DDIs and in attributing DDIs' severity. The level of agreement among five ICs (i.e. INTERCheck WEB, Micromedex, Lexicomp, Epocrates, and drugs.com) in identifying potential DDIs and in attributing severity categories was evaluated using Gwet's AC1 on all five ICs and by comparing groups of 4- and 2-pair sets of ICs. A total of 486 potentially interacting drugs with dabigatran, 556 for apixaban, 444 for edoxaban, and 561 for rivaroxaban were reported. The level of agreement among the ICs in identifying potential DDIs was poor (range: 0.12-0.16). Similarly, it was low in 4 and 2-sets analyses. The level of agreement among the ICs in classifying the severity of potential DDIs was poor (range: 0.32-0.34), also in 4 and 2-sets analyses. The heterogeneity among different ICs and SPCs underscores the need to standardize DDIs datasets and to conduct real-world studies to generate evidence regarding the frequency and clinical relevance of potential DOACs-related DDIs.

Sections du résumé

BACKGROUND UNASSIGNED
Direct oral anticoagulants (DOACs) may be involved in drug-drug interactions (DDIs) potentially increasing the risk of adverse drug reactions. This study aimed to evaluate the level of agreement among interaction checkers (ICs) and DOACs' summary of product characteristics (SPCs), in listing DDIs and in attributing DDIs' severity.
RESEARCH DESIGN AND METHODS UNASSIGNED
The level of agreement among five ICs (i.e. INTERCheck WEB, Micromedex, Lexicomp, Epocrates, and drugs.com) in identifying potential DDIs and in attributing severity categories was evaluated using Gwet's AC1 on all five ICs and by comparing groups of 4- and 2-pair sets of ICs.
RESULTS UNASSIGNED
A total of 486 potentially interacting drugs with dabigatran, 556 for apixaban, 444 for edoxaban, and 561 for rivaroxaban were reported. The level of agreement among the ICs in identifying potential DDIs was poor (range: 0.12-0.16). Similarly, it was low in 4 and 2-sets analyses. The level of agreement among the ICs in classifying the severity of potential DDIs was poor (range: 0.32-0.34), also in 4 and 2-sets analyses.
CONCLUSIONS UNASSIGNED
The heterogeneity among different ICs and SPCs underscores the need to standardize DDIs datasets and to conduct real-world studies to generate evidence regarding the frequency and clinical relevance of potential DOACs-related DDIs.

Identifiants

pubmed: 38386102
doi: 10.1080/17425255.2024.2322134
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Massimo Carollo (M)

Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

Salvatore Crisafulli (S)

Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

Francesco Ciccimarra (F)

Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

Giuseppe Andò (G)

Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Igor Diemberger (I)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Gianluca Trifirò (G)

Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

Classifications MeSH